However, the price of Gilead's drug, Sovaldi, has raised serious questions about just what the cost of the drug should be. Sovaldi was in the spotlight in March after Henry Waxman wrote a letter to Gilead CEO Dr. John C. Martin asking for Dr. Martin to explain the $1,000 a pill price tag his company had attached to the treatment.
In this clip, though, CNBC contributor Barbara Ryan observes that the price tag of the drug should be kept in the context of its benefits, including potentially saving lives as well as eliminating the downstream costs associated with Hep C and the liver damage it causes. It's a different perspective, and certainly one friendlier to the biotech industry than the tone that Waxman set in his letter. But it's certainly worth noting that Sovaldi should ultimately result in dramatic reductions in health care costs for its patients if it results in a viable treatment for Hep C.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer